-
1
-
-
0000295746
-
Cases of sarcoma and Hodgkin's disease treated by exposure to X-rays: A preliminary report
-
Pusey WA. Cases of sarcoma and Hodgkin's disease treated by exposure to X-rays: a preliminary report. JAMA 1902;38:166-169.
-
(1902)
JAMA
, vol.38
, pp. 166-169
-
-
Pusey, W.A.1
-
2
-
-
0001613360
-
Therapeutical value of roentgen ray in treatment of pseudoleukemia
-
Senn N. Therapeutical value of roentgen ray in treatment of pseudoleukemia. New York Med J 1903;77:665-668.
-
(1903)
New York Med J
, vol.77
, pp. 665-668
-
-
Senn, N.1
-
3
-
-
0018822166
-
Curability of advanced Hodgkin's disease with chemotherapy: Long-term follow-up of MOPP-treated patients at the National Cancer Institute
-
DeVita VT Jr, Simon RM, Hubbard G et al. Curability of advanced Hodgkin's disease with chemotherapy: long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980;92:587-595.
-
(1980)
Ann Intern Med
, vol.92
, pp. 587-595
-
-
DeVita V.T., Jr.1
Simon, R.M.2
Hubbard, G.3
-
4
-
-
0016707139
-
Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP
-
Bonadonna G, Zucali R, Monfardini S et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975; 36:252-260.
-
(1975)
Cancer
, vol.36
, pp. 252-260
-
-
Bonadonna, G.1
Zucali, R.2
Monfardini, S.3
-
5
-
-
0004270741
-
-
Cambridge: Harvard University Press
-
Kaplan H. Hodgkin's disease. Cambridge: Harvard University Press, 1980:2.
-
(1980)
Hodgkin's Disease
, pp. 2
-
-
Kaplan, H.1
-
6
-
-
0027315157
-
Recent results on the biology of Hodgkin and Reed-Sternberg cells II: Continuous cell lines
-
Drexler H. Recent results on the biology of Hodgkin and Reed-Sternberg cells II: continuous cell lines. Leuk Lymphoma 1993;9:1-24.
-
(1993)
Leuk Lymphoma
, vol.9
, pp. 1-24
-
-
Drexler, H.1
-
7
-
-
0027935346
-
The cellular biology of the Reed-Sternberg cell
-
Haluska FG, Brufsky AM, Canellos GP et al. The cellular biology of the Reed-Sternberg cell. Blood 1994;84:1005-1015.
-
(1994)
Blood
, vol.84
, pp. 1005-1015
-
-
Haluska, F.G.1
Brufsky, A.M.2
Canellos, G.P.3
-
8
-
-
0031919997
-
The origin of Hodgkin and Reed-Sternberg cells
-
Küppers R, Rajewsky K. The origin of Hodgkin and Reed-Sternberg cells. Annu Rev Immunol 1998;16:471-479.
-
(1998)
Annu Rev Immunol
, vol.16
, pp. 471-479
-
-
Küppers, R.1
Rajewsky, K.2
-
9
-
-
0029952779
-
Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells
-
Kanzler H, Küppers R, Hansmann ML et al: Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996;184:1495-1505.
-
(1996)
J Exp Med
, vol.184
, pp. 1495-1505
-
-
Kanzler, H.1
Küppers, R.2
Hansmann, M.L.3
-
10
-
-
0030834265
-
Hodgkin Reed-Sternberg cells in lymphocyte predominant Hodgkin's disease represent clonal population of germinal center-derived tumor cells
-
Braeuninger A, Küppers R, Strickler JG et al: Hodgkin Reed-Sternberg cells in lymphocyte predominant Hodgkin's disease represent clonal population of germinal center-derived tumor cells. Proc Natl Acad Sci 1997;94:9337-9342.
-
(1997)
Proc Natl Acad Sci
, vol.94
, pp. 9337-9342
-
-
Braeuninger, A.1
Küppers, R.2
Strickler, J.G.3
-
12
-
-
0023849566
-
Clinical stages I and II Hodgkin's disease: A specifically tailored therapy according to prognostic factors
-
Carde P, Burger JM, Henry-Amar M. Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol 1988;6:239-248.
-
(1988)
J Clin Oncol
, vol.6
, pp. 239-248
-
-
Carde, P.1
Burger, J.M.2
Henry-Amar, M.3
-
13
-
-
0024796020
-
Risk factor adapted treatment of Hodgkin's lymphoma: Strategies and perspectives. Recent Results
-
Loeffler M, Pfreundschuh M, Rühl U. Risk factor adapted treatment of Hodgkin's lymphoma: strategies and perspectives. Recent Results. Cancer Res 1989;117:142.
-
(1989)
Cancer Res
, vol.117
, pp. 142
-
-
Loeffler, M.1
Pfreundschuh, M.2
Rühl, U.3
-
14
-
-
0032548107
-
A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease
-
Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339:1506.
-
(1998)
N Engl J Med
, vol.339
, pp. 1506
-
-
Hasenclever, D.1
Diehl, V.2
-
15
-
-
0005397035
-
Final results of a randomized trial (HD4): 30 Gy extended field plus 10 Gy involved field radiation is equally effective to 40 Gy extended field radiation in patients with Hodgkin's disease PS I/II
-
Rüffer U, Sieber M, Tesch H. Final results of a randomized trial (HD4): 30 Gy extended field plus 10 Gy involved field radiation is equally effective to 40 Gy extended field radiation in patients with Hodgkin's disease PS I/II. Blood 1997;90(suppl):143.
-
(1997)
Blood
, vol.90
, Issue.SUPPL.
, pp. 143
-
-
Rüffer, U.1
Sieber, M.2
Tesch, H.3
-
17
-
-
0001258960
-
Involved field radiation is as effective as extended field radiation following chemotherapy for intermediate stage Hodgkin's disease expecting a reduction of long term side-effects: Interim analysis of the HD8 trial (GHSG)
-
Rüffer U, Sieber M, Pfistner B et al. Involved field radiation is as effective as extended field radiation following chemotherapy for intermediate stage Hodgkin's disease expecting a reduction of long term side-effects: interim analysis of the HD8 trial (GHSG). Ann Oncol 1999;10(suppl 3):250.
-
(1999)
Ann Oncol
, vol.10
, Issue.SUPPL. 3
, pp. 250
-
-
Rüffer, U.1
Sieber, M.2
Pfistner, B.3
-
18
-
-
0026439199
-
Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
-
Canellos GP, Anderson JR, Propert KJ. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-1485.
-
(1992)
N Engl J Med
, vol.327
, pp. 1478-1485
-
-
Canellos, G.P.1
Anderson, J.R.2
Propert, K.J.3
-
19
-
-
8244252294
-
Treatment of advanced Hodgkin's disease with chemotherapy-comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada Clinical Trials Group
-
Connors JM, Klimo P, Adams G et al. Treatment of advanced Hodgkin's disease with chemotherapy-comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997;15:1638-1645.
-
(1997)
J Clin Oncol
, vol.15
, pp. 1638-1645
-
-
Connors, J.M.1
Klimo, P.2
Adams, G.3
-
20
-
-
0021075273
-
A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy
-
Carde P, MacKintosh F, Rosenberg S. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol 1983;1:146-153.
-
(1983)
J Clin Oncol
, vol.1
, pp. 146-153
-
-
Carde, P.1
MacKintosh, F.2
Rosenberg, S.3
-
21
-
-
0028988635
-
Brief chemotherapy, Stanfotd V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report
-
Bartlett N, Rosenberg S, Hoppe R et al. Brief chemotherapy, Stanfotd V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol 1995;13:1080-1089.
-
(1995)
J Clin Oncol
, vol.13
, pp. 1080-1089
-
-
Bartlett, N.1
Rosenberg, S.2
Hoppe, R.3
-
22
-
-
0032422646
-
BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's Lymphoma Study Group
-
Diehl V, Franklin J, Hasenclever D et al: BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 1998; 16:3810-3819.
-
(1998)
J Clin Oncol
, vol.16
, pp. 3810-3819
-
-
Diehl, V.1
Franklin, J.2
Hasenclever, D.3
-
23
-
-
0031887688
-
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group
-
Loeffler M, Brosteanu O, Hasenclever D et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group J Clin Oncol 1998;16:818.
-
(1998)
J Clin Oncol
, vol.16
, pp. 818
-
-
Loeffler, M.1
Brosteanu, O.2
Hasenclever, D.3
-
24
-
-
0015399024
-
Combination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapy
-
Cannellos G, Young RC, DeVita VD. Combination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapy. Clin Pharm Ther 1972;13:750-758.
-
(1972)
Clin Pharm Ther
, vol.13
, pp. 750-758
-
-
Cannellos, G.1
Young, R.C.2
DeVita, V.D.3
-
25
-
-
0022608592
-
Salvage chemotherapy in Hodgkin's disease irradiation failures: Superiority of doxorubicin-containing regimens over MOPP
-
Santoro A, Viviani S, Villarreal C et al: Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP. Cancer Treat Rep 1986;70:343-351.
-
(1986)
Cancer Treat Rep
, vol.70
, pp. 343-351
-
-
Santoro, A.1
Viviani, S.2
Villarreal, C.3
-
26
-
-
0018744297
-
Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse
-
Fisher R, De VV, Hubbard S et al: Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Int Med 1979;90:761-768.
-
(1979)
Ann Int Med
, vol.90
, pp. 761-768
-
-
Fisher, R.1
De, V.V.2
Hubbard, S.3
-
27
-
-
0026558372
-
Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure
-
Longo D, Duffey P, Young R et al: Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992;10:210-219.
-
(1992)
J Clin Oncol
, vol.10
, pp. 210-219
-
-
Longo, D.1
Duffey, P.2
Young, R.3
-
28
-
-
0022982371
-
CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease
-
Santoro A, Viviani S, Valagussa P et al. CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease. Semin Oncol 1986;13:23-32.
-
(1986)
Semin Oncol
, vol.13
, pp. 23-32
-
-
Santoro, A.1
Viviani, S.2
Valagussa, P.3
-
29
-
-
0025608296
-
Phase II study of MOPLACE chemotherapy for patients with previously treated Hodgkin's disease: A CALGB study
-
Schulman P, McCarroll K, Cooper M et al. Phase II study of MOPLACE chemotherapy for patients with previously treated Hodgkin's disease: a CALGB study. Med Ped Oncol 1990;18:482-490.
-
(1990)
Med Ped Oncol
, vol.18
, pp. 482-490
-
-
Schulman, P.1
McCarroll, K.2
Cooper, M.3
-
30
-
-
0028285134
-
Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: A trial of the German Hodgkin's Disease Study Group
-
Pfreundschuh M, Rueffer U, Lathan B et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. J Clin Oncol 1994;12:580-592.
-
(1994)
J Clin Oncol
, vol.12
, pp. 580-592
-
-
Pfreundschuh, M.1
Rueffer, U.2
Lathan, B.3
-
31
-
-
0023267126
-
MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease
-
Hagemeister F, Tannir N, McLaughlin P et al. MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. J Clin Oncol 1987;5:556-563
-
(1987)
J Clin Oncol
, vol.5
, pp. 556-563
-
-
Hagemeister, F.1
Tannir, N.2
McLaughlin, P.3
-
32
-
-
0033153007
-
ASHAP: A regimen for cytoreduction of refractory or recurrent Hodgkin's disease
-
Rodriguez J, Rodriguez M, Fayad L et al. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood 1999;93:3632-3641.
-
(1999)
Blood
, vol.93
, pp. 3632-3641
-
-
Rodriguez, J.1
Rodriguez, M.2
Fayad, L.3
-
33
-
-
0023484082
-
Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's disease refractory to cyclophosphamide, vincristine, procarbacine, and prednisone (COPP) and doxorubicine, bleomycin, vinblastine, and darcarbazine (ABVD): A multi-center trial of the German Hodgkin's study group
-
Pfreundschuh MG, Schoppe WD, Fuchs R. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's disease refractory to cyclophosphamide, vincristine, procarbacine, and prednisone (COPP) and doxorubicine, bleomycin, vinblastine, and darcarbazine (ABVD): a multi-center trial of the German Hodgkin's study group. Cancer Treatment Reports 1987;71:1203-1212.
-
(1987)
Cancer Treatment Reports
, vol.71
, pp. 1203-1212
-
-
Pfreundschuh, M.G.1
Schoppe, W.D.2
Fuchs, R.3
-
34
-
-
0028819356
-
Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation
-
Cowill R, Crump M, Couture F. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 1995;13:396-403.
-
(1995)
J Clin Oncol
, vol.13
, pp. 396-403
-
-
Cowill, R.1
Crump, M.2
Couture, F.3
-
35
-
-
0003345877
-
Dexamethasone, high-dose ara-C and cisplatin as salvage treatment for relapsing Hodgkin's disease
-
Velasquez WS, Jagannath S, Hagemeister FB. Dexamethasone, high-dose ara-C and cisplatin as salvage treatment for relapsing Hodgkin's disease. Proc Am Soc Hematol 1986; 68:242-249.
-
(1986)
Proc Am Soc Hematol
, vol.68
, pp. 242-249
-
-
Velasquez, W.S.1
Jagannath, S.2
Hagemeister, F.B.3
-
36
-
-
0030710532
-
High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: Results from the EBMT. (Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.)
-
Sweetenham J, Taghipour G, Milligan D et al. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. (Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.) Bone Marrow Transplant 1997;20:745-751.
-
(1997)
Bone Marrow Transplant
, vol.20
, pp. 745-751
-
-
Sweetenham, J.1
Taghipour, G.2
Milligan, D.3
-
37
-
-
0027374883
-
High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long-term follow-up in 128 patients
-
Bierman P, Bagin R, Jagannath S et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients. Ann Oncol 1993;4:767-774.
-
(1993)
Ann Oncol
, vol.4
, pp. 767-774
-
-
Bierman, P.1
Bagin, R.2
Jagannath, S.3
-
38
-
-
0025228997
-
High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease
-
Jones R, Piantadosi S, Mann R et al. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1990;8:527-534.
-
(1990)
J Clin Oncol
, vol.8
, pp. 527-534
-
-
Jones, R.1
Piantadosi, S.2
Mann, R.3
-
39
-
-
0031967030
-
Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa-BEAM)
-
Josting A, Katay I, Rueffer U et al. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa-BEAM). Ann Oncol 1998;9:289-296.
-
(1998)
Ann Oncol
, vol.9
, pp. 289-296
-
-
Josting, A.1
Katay, I.2
Rueffer, U.3
-
40
-
-
0025945351
-
Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease
-
Gianni A, Siena S, Bregni M et al. Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease. Ann Oncol 1991;2:645-652.
-
(1991)
Ann Oncol
, vol.2
, pp. 645-652
-
-
Gianni, A.1
Siena, S.2
Bregni, M.3
-
41
-
-
0026329564
-
Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease
-
Armitage J, Bierman P, Vose J et al. Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease. Am J Med 1991;91:605-612.
-
(1991)
Am J Med
, vol.91
, pp. 605-612
-
-
Armitage, J.1
Bierman, P.2
Vose, J.3
-
42
-
-
0027404777
-
Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial
-
Linch D, Winfield D, Goldstone A et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993;341:1051.
-
(1993)
Lancet
, vol.341
, pp. 1051
-
-
Linch, D.1
Winfield, D.2
Goldstone, A.3
-
43
-
-
0002992983
-
HDR-1: High-dose therapy (HDT) followed by hematopoietic stem cell transplantation (HSCT) for relapsed chemosensitive Hodgkin's disease (HD): Final results of a randomized GHSG and EBMT trial (HD-R1)
-
Schmitz N, Sextro M, Pfistner B. HDR-1: High-dose therapy (HDT) followed by hematopoietic stem cell transplantation (HSCT) for relapsed chemosensitive Hodgkin's disease (HD): final results of a randomized GHSG and EBMT trial (HD-R1). Proc Am Soc Clin Oncol 1999; 5(suppl): 18.
-
(1999)
Proc Am Soc Clin Oncol
, vol.5
, Issue.SUPPL.
, pp. 18
-
-
Schmitz, N.1
Sextro, M.2
Pfistner, B.3
|